Koers Biocept Inc Nasdaq
Aandelen
US09072V2043
Medische apparatuur, benodigdheden & distributie
Omzet 2021 | 61,25 mln. 56,88 mln. | Omzet 2022 | 25,86 mln. 24,01 mln. | Marktkapitalisatie | 9,04 mln. 8,4 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2021 | -2 mln. -1,86 mln. | Nettowinst (verlies) 2022 | -32 mln. -29,72 mln. | EV/omzet 2021 | 0,73 x |
Nettoliquiditeiten 2021 | 16,19 mln. 15,04 mln. | Nettoliquiditeiten 2022 | 788K 732K | EV/omzet 2022 | 0,32 x |
K/w-verhouding 2021 |
-18,9
x | K/w-verhouding 2022 |
-0,28
x | Werknemers | - |
Dividendrendement 2021 * |
-
| Dividendrendement 2022 |
-
| Vrij verhandelbaar | 100% |
Recentste transcriptie over Biocept Inc
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Barbara Blouw
CTO | Chief Tech/Sci/R&D Officer | - | 01-01-20 |
Nathaniel Sweed
CTO | Chief Tech/Sci/R&D Officer | - | - |
Chief Operating Officer | 60 | 08-03-22 |
Vaira. 1 jan. | Kapi. | |
---|---|---|
-1,19% | 12,65 mld. | |
-6,06% | 8,01 mld. | |
-0,28% | 5,35 mld. | |
+21,79% | 5,23 mld. | |
+2,05% | 4,69 mld. | |
-51,30% | 3,26 mld. | |
+7,80% | 2,64 mld. | |
-8,63% | 2,23 mld. | |
-0,96% | 1,94 mld. |